Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Under $0.50 stocks -- Ignore unavailable to you. Want to Upgrade?

To: jmhollen who wrote (147)	2/20/2009 12:05:51 AM
From: Gary Mohilner	Respond to of 150

I believe anyone looking at stocks under $.50 should take a good look at GNVC. The company has many drugs in development, and one that could be approved next year, TNFerade for pancreatic cancer. I very much suggest listening and looking at the presentation they made at the BIO Conference last week, you can find it on the Genvec website. Clearly the stock's hurting due to low cash, however they've recently laid off personnel to send potential partners in TNFerade a message, if they must, they can take TNFerade to Approval and then a partner will pay dramatically more. The company has expressed the desire to keep the U.S. market for itself, but partner the drug in the rest of the world. There are companies who apparently are interested, but giant Pharma's have been picking off drugs and companies at bargain basement prices, I don't think GNVC will sell for substantially less than they believe the drug is worth. There is also the likelyhood that one or more of the Foot and Mouth Vaccines GNVC has under trials by Homeland Security will be approved and ordered in mass by them late this year, or early next. GNVC among other drugs has Malaria Vaccines under trials by the U.S. Navy for the DOD, they can purchase the drug on being satisfied with it without FDA Approval for the entire DOD, but naturally the company will want FDA and eventual worldwide approval to maximize sales. Gary